Phenotypical Approach of the Drug Metabolizing Hormones Activity Before and After Roux-en Y-Gastric Bypass (SODA)
Phenotypical Approach of the Drug Metabolizing Hormones Activity (CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4 and P-gp) Before and After Roux-en Y-Gastric Bypass. The SODA Protocol: Surgery for Obesity and Drug Availability
The activity of drug-metabolizing enzymes and transporters evolutes after Roux-en-Y gastric Bypass.
Primary aim : To study the intra individual evolution of phenotypical markers of different drug metabolizing enzymes and one transporter (CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4 and P-gp), using a cocktail phenotypic approach, after Roux-en-Y gastric Bypass.
研究概览
详细说明
Principal Judgement criteria :
Phenotypical markers of enzymes and transporter activity before, at 5-8 weeks and 25-30 weeks following surgery.
Secondary judgement criteria :
- Genetic polymorphisms known to affect expression and/or activity of enzymes and transporter.
- Intestinal and hepatic expression and activity of the enzymes and transporter of interest.
- Markers of inflammation Methodology, study design : open-labelled monocentric study.
Sample size : It will be a descriptive experimental study involving 12 subjects.
Study design : In centre 1: Inclusion at least 2 weeks prior to surgery (V0)
In centre 2: Three studies of 12 hours each will occur (in addition with the usual clinical and surgical follow up) at three times periods: in the 8 weeks period before surgery (V1), at 5-8 weeks after surgery (V2) and at 25-30 weeks after surgery (V3).
In centre 3: the patients will undergo gastric bypass surgery (corresponding to the usual clinical and surgical follow up) and samples of jejunum and liver will be obtain during the surgery (J0).
Centres 4 and 5 are involved in samples analysis.Hence, patients will attend 3 visits, in addition to the usual clinical and surgical follow-up.
Study duration: 26 months (with duration of inclusion of 18 months)
Duration for a patient: 38 weeks at maximum (8 months)
Investigating center and participating units: one center enrolling the patients and three centers involving in the others investigations.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Paris、法国、75010
- Unit of internal medicine A, Lariboisière Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients with morbid obesity (IMC > 40 kg/m²) or severe obesity (IMC=35-40 kg/m²) with co morbidities (sleep apnea syndrome or hypertension without treatment or steatosis hepatitis) candidates for a gastric bypass.
- Patient not receiving more than two treatments whose effect on the expression of enzymes and drug transporters is zero other than vitamins.
- Patient agreeing to participate at three studies of one day (12 hours) occurring at three different periods.
- Patients aged between 18 and 60 years old.
- Patient giving its well-informed and free consent.
- Patient without allergy to any of the drugs used for test.
- Patients living in France during the study and with French social security
Exclusion Criteria:
- Tabacco
- Contraception including estrogens compounds
- Medication other than vitamins.
- Allergy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:phenotypical approach
|
each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phenotypical markers of enzymes and transporter activity
大体时间:at 5-8weeks
|
plasmatic [Paraxanthine/caffeine] ratio (T4H) at 5-8 weeks following surgery.
- plasmatic [Omeprazole/5-hydroxyomeprazole] ratio (T4H) at 5-8 weeks following surgery.
- urinary Log (dextromethorphan/dextrorphan) (T0-T8h) at 5-8 weeks following surgery.
- urinary Losartan/ E-3174 (T0-8h) at 5-8 weeks following surgery.
- plasmatic AUC 0-inf midazolam at 5-8 weeks following surgery.
- plasmatic AUC 0-inf digoxin at 5-8 weeks following surgery
|
at 5-8weeks
|
|
Phenotypical markers of enzymes and transporter activity
大体时间:25-30 weeks
|
plasmatic [Paraxanthine/caffeine] ratio (T4H) at 25-30 weeks following surgery.
- plasmatic [Omeprazole/5-hydroxyomeprazole] ratio (T4H) at 25-30 weeks following surgery.
- urinary Log (dextromethorphan/dextrorphan) (T0-T8h) at 25-30 weeks following surgery.
- urinary Losartan/ E-3174 (T0-8h) at 25-30 weeks following surgery.
- plasmatic AUC 0-inf midazolam at 25-30 weeks following surgery.
- plasmatic AUC 0-inf digoxin at 25-30 weeks following surgery
|
25-30 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Intestinal and hepatic expression and activity of the enzymes and transporter of interest and markers of inflammation
大体时间:before surgery
|
Intestinal and hepatic expression and activity of the enzymes and transporter of interest and markers of inflammation
|
before surgery
|
合作者和调查者
调查人员
- 首席研究员:Célia LLORET-LINARES, MD,、Assistance Publique - Hôpitaux de Paris
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- P100506
- 2011-A00312-39 (其他标识符:IDRCB)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.